Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4702—Regulators; Modulating activity
  • C07K14/4703—Inhibitors; Suppressors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2799/00—Uses of viruses
  • C12N2799/02—Uses of viruses as vector
  • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Definitions

• TCCs transitional cell carcinomas
• LH heterozygosity
• chromosome 9q and/or 9p the most frequent genetic alteration (>50%) in both superficial papillary and invasive TCC
• the present invention provides an isolated nucleic acid molecule comprising the nucleotide of the DBCCRl gene as set out in figure 6, or alleles thereof.
• the present invention also provides nucleic acid molecules including polymorphisms of the figure 6 nucleic acid sequence, for example, the silent polymorphisms selected from the group consisting of T1036C, C2044A and T2642C (see below) .
• the present invention also includes the first characterisation of the genomic structure of the DBCCRl gene see the intron/exon information in table 2, as well as the sequencing of the coding region shown in figure 6. The sequence of the DBCCRl promoter region is set out in figure 11.
• the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a DBCCRl polypeptide having the amino acid sequence set out in figure 6.
• the present invention provides the use of the above substances in the preparation of a medicament for treating cancer, especially bladder cancer.
• the present invention provides the use of a polymorphism in the DBCCRl nucleic acid sequence as a genetic marker within the 9q32-33 locus, and more particularly within the interval between D9S1848 and AFMA239XA9.
• a polymorphism in the DBCCRl nucleic acid sequence as a genetic marker within the 9q32-33 locus, and more particularly within the interval between D9S1848 and AFMA239XA9.
• the use of genetic markers is well known in the art and they are valuable tools for the identification and mapping of genes. Examples of polymorphisms include the T1036C, C2044A and T2642C polymorphisms described below.
• the present invention provides a method for determining the inactivation of the DBCCRl gene, the method comprising determining the methylation in the DBCCRl promoter region or gene .
• Methods for quantitating methylation differences between nucleic acid sequences are discussed below. These include: (a) the use of methylation sensitive single nucleotide primer extension (Ms-SNuPE) .
• the present invention provides the use of a methylation inhibitor in the preparation of a medicament for treating cancer, especially bladder cancer, wherein the methylation inhibitor causes activation of the tumour suppressor activity of the DBCCRl gene, e.g. by allowing the production of active DBCCRl polypeptide.
• FIG. 3 A YAC contig map encompassing the deleted region at 9q32-33. 3EG8, 21GH3, 36GD9, 15HD3, 12IB1, 28BB3, 9EE5, 9DC8 and 21GH3 are from the ICI YAC library and other YACs are from the CEPH YAC library. Black squares and white squares indicate presence or absence of a particular STS in each YAC, respectively.
• the encoded polypeptide may comprise an amino acid sequence which differs by one or more amino acid residues from the amino acid sequence shown in figure 6.
• Nucleic acid encoding a polypeptide which is an amino acid sequence variant, derivative, or allele of the sequence shown in figure 6 is further provided by the present invention. Such polypeptides are discussed below. Nucleic acid encoding such a polypeptide may show greater than about 60% homology with the coding sequence shown in figure 6 greater than about 70% homology, greater than about 80% homology, greater than about 90% homology, or greater than about 95% homology.
• DBCCRl sequences can be incorporated in a vector having control sequences operably linked to the DBCCRl nucleic acid to control its expression.
• the vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted nucleic acid, nucleic acid sequences so that the DBCCRl polypeptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide produced in the host cell is secreted from the cell.
• hybridisation will generally be preceded by denaturation to produce single- stranded DNA.
• the hybridisation may be as part of a PCR procedure, or as part of a probing procedure not involving PCR.
• An example procedure would be a combination of PCR and low stringency hybridisation.
• a screening procedure chosen from the many available to those skilled in the art, is used to identify successful hybridisation events and isolated hybridised nucleic acid.
• Marker genes such as antibiotic resistance or sensitivity genes may be used in identifying clones containing nucleic acid of interest, as is well known in the art .
• the introduction may be followed by causing or allowing expression from the nucleic acid, e.g. by culturing host cells (which may include cells actually transformed although more likely the cells will be descendants of the transformed cells) under conditions for expression of the gene, so that the encoded polypeptide is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium.
• a polypeptide may be isolated and/or purified from the host cell and/or culture medium, as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers (e.g. see below).
• Preferred antibodies according to the invention are isolated, in the sense of being free from contaminants such as antibodies able to bind other polypeptides and/or free of serum components. Monoclonal antibodies are preferred for some purposes, though polyclonal antibodies are within the scope of the present invention.
• Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest.
• Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression.
• the invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.
• the reactivities of antibodies on a sample may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility.
• the reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals.
• the linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non- covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.
• the above methods can carried out following the digestion of bisulphite-converted DNA to convert unmethylated cytosine to be converted to uracil.
• the use of bisulphite to treat the DNA means that the uracil from the unmethylated cytosine is replicated as thymine during subsequent PCR.
• methylcytosine is resistant to deamination and is therefore replicated as cytosine during amplification.
• quantitation of the ratio of methylated: unmethylated cytosine (C:T) allows the extent of methylation in a nucleic acid sequence to be determined and correlated to standards, e.g. to diagnose the presence of a tumour or a urothelial condition predisposed to develop cancer.
• the C:T ratio can be determined by incubating the isolated PCR product, primers and Taq polymerase with either [ 32 P] dCTP or P 2 P] dTTP followed by denaturing gel electrophoresis and phosphoimage analysis.
• a specific amplification reaction such as PCR using one or more pairs of primers may be employed to amplify the region of interest in the nucleic acid, for instance the DBCCRl gene or a particular region in which mutations associated with cancer.
• Exemplary primers for this purpose are shown in table 2.
• the amplified nucleic acid may then be sequenced as above, and/or tested in any other way to determine the presence or absence of a particular feature.
• Nucleic acid for testing may be prepared from nucleic acid removed from cells or in a library using a variety of other techniques such as restriction enzyme digest and electrophoresis.
• Allele- or variant-specific oligonucleotides may similarly be used in PCR to specifically amplify particular sequences if present in a test sample.
• Assessment of whether a PCR band contains a gene variant may be carried out in a number of ways familiar to those skilled in the art .
• the PCR product may for instance be treated in a way that enables one to display the mutation or polymorphism on a denaturing polyacrylamide DNA sequencing gel, with specific bands that are linked to the gene variants being selected .
• administration is preferably in a "prophylactically effective amount” or a "therapeutically effective amount” (as the case may be, although prophylaxis may be considered therapy) , this being sufficient to show benefit to the individual.
• a prophylaxis may be considered therapy
• the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
• a composition may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated.
• Methods of Gene Therapy are described below.
• the nucleic acid encoded the authentic biologically active DBCCRl polypeptide could be used in a method of gene therapy, to treat a patient who is unable to synthesize the active polypeptide or unable to synthesize it at the normal level, thereby providing the tumour suppressing or growth inhibiting effect provided by wild-type DBCCRl, and thereby suppressing the occurrence of cancer and/or reduce the size or extent of existing cancer in the target cells.
• the aim of gene therapy using nucleic acid encoding the DBCCRl polypeptide, or an active portion thereof is to increase the amount of the expression product of the nucleic acid in cells in which the level of the wild-type DBCCRl polypeptide is absent or present only at reduced levels.
• Such treatment may be therapeutic in the treatment of cells which are already cancerous .
• the substance may be investigated further. Furthermore, it may be manufactured and/or used in preparation, i.e. manufacture or formulation, of a composition such as a medicament, pharmaceutical composition or drug. These may be administered to individuals.
• RACE 5' RACE was performed to characterize the 5' sequence of the IB3089A gene using a human fetal brain Clontech Marathon cDNA amplification kit according to the manufacture's protocol (Clontech).
• RACE-PCR was carried out with a primer 5' -CTTCTCTTGCAGATACTGAGGA (nt 1141-1119) and a primer API, which was provided in the kit.
• the product was electrophoresed on agarose gel, alkali-blotted onto the nylon membrane, and probed with a oligonucleotide probe 5'- GGTAGGTCTCCTGCCAAGCA end-labelled with 32 P.
• IB3089A a novel gene, in a bladder cancer-tumour suppressor region at 9q32-33.
• Expression of IB3089A was frequently down regulated in bladder cancer cells in vitro and thus can be reversed by treatment with a demethylating agent.
• Our results indicate that downregulation of IB3089A expression in bladder caner cells lines and bladder tumours is due to hypermethylation of the 5' region of the gene.
• IB 1 -L 1 CCATGGTTTGAACTGCAGTGTA

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Urology & Nephrology (AREA)
• Gastroenterology & Hepatology (AREA)
• Reproductive Health (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Endocrinology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Dermatology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=10813172

Family Applications (1)

Country Status (6)

Families Citing this family (15)

Family Cites Families (1)

• 1997
  • 1997-05-28 GB GBGB9710995.3A patent/GB9710995D0/en active Pending
• 1998
  • 1998-05-26 EP EP98922966A patent/EP0983355A1/en not_active Withdrawn
  • 1998-05-26 WO PCT/GB1998/001515 patent/WO1998054318A1/en active IP Right Grant
  • 1998-05-26 JP JP50036199A patent/JP2002511749A/ja active Pending
  • 1998-05-26 CA CA002288235A patent/CA2288235A1/en not_active Abandoned
  • 1998-05-26 AU AU75425/98A patent/AU752701B2/en not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events